Related Experiment Videos
The neurofibromatosis type I messenger RNA undergoes base-modification RNA editing
G R Skuse1, A J Cappione, M Sowden
1Department of Medicine, University of Rochester School of Medicine and Dentistry, NY 14642, USA.
Nucleic Acids Research
|February 1, 1996
Summary
Neurofibromatosis type I (NF1) mRNA editing, crucial for tumor suppression, is elevated in tumors. This RNA editing process differs from apolipoprotein B (apoB) mRNA editing, suggesting distinct regulatory factors are involved.
Area of Science:
- Molecular Biology
- Genetics
- Biochemistry
Background:
- A functional mooring sequence is essential for apolipoprotein B (apoB) mRNA editing.
- This sequence is also present in the messenger RNA (mRNA) for the neurofibromatosis type I (NF1) tumor suppressor.
- NF1 mRNA editing involves changing a cytidine to a uridine at nucleotide 2914, creating a premature stop codon.
Purpose of the Study:
- To investigate the mechanism and regulation of NF1 mRNA editing.
- To compare NF1 mRNA editing with apoB mRNA editing.
- To identify potential trans-acting factors involved in NF1 editing.
Main Methods:
- In vitro RNA editing assays.
- Cellular transfection assays using neural tumor and hepatoma cells.
- Analysis of APOBEC-1 dependence for NF1 editing.
Main Results:
- NF1 mRNA editing occurs in normal tissues and is significantly higher in tumors.
- Both NF1 and apoB mRNA editing can occur in neural tumor and hepatoma cells.
- NF1 mRNA editing does not appear to be dependent on rate-limiting amounts of APOBEC-1.
Conclusions:
- NF1 mRNA editing is a distinct process from apoB mRNA editing.
- Different trans-acting factors likely regulate NF1 and apoB RNA editing.
- The elevated NF1 editing in tumors may have implications for NF1 tumor suppressor function.